Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | WNT3A | P56704 | 1/20 | 0.30 |
| ▸ | MYC | P01106 | 1/20 | 0.30 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | CRHBP | P24387 | 2/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19928557 | 0.97 | DRD1 (0.36) | DRD1MAP3K14SMN1; SMN2GAAITGB2 | |
| SCHEMBL3136613 | 0.91 | ITGB2 (0.39) | DRD1SMN1; SMN2GAAITGB2ICAM1 | |
| SCHEMBL13243539 | 0.90 | ITGB2 (0.38) | DRD1SMN1; SMN2GAAITGB2ICAM1 | |
| SCHEMBL3133241 | 0.90 | ITGB2 (0.38) | DRD1SMN1; SMN2GAAITGB2ICAM1 | |
| SCHEMBL20351197 | 0.90 | ITGB2 (0.38) | DRD1SMN1; SMN2GAAITGB2ICAM1 | |
| SCHEMBL17426095 | 0.88 | ABCG2 (0.38) | DRD1MAP3K14SMN1; SMN2CYP3A4TDP1 | |
| SCHEMBL372145 | 0.88 | ITGB2 (0.39) | DRD1SMN1; SMN2GAAITGB2ICAM1 | |
| SCHEMBL3132985 | 0.85 | ITGB2 (0.46) | DRD1SMN1; SMN2GAAITGB2ICAM1 | |
| SCHEMBL7159681 | 0.81 | LMNA (0.33) | MAP3K14SMN1; SMN2GAAITGB2ICAM1 | |
| SCHEMBL21201776 | 0.81 | DRD1 (0.32) | DRD1ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908888-B2 | Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160257687-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2016-09-08 | — | — | US | disclosed |
| US-9000161-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-8993582-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-8883806-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130253191-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253190-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8501967-B2 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8410265-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120316350-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE 1-SUBSTITUTED-3-AMINOALCOHOLS | LONZA AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-8258338-B2 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8198468-B2 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2012-06-12 | — | — | US | disclosed |
| US-8193380-B2 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20110207945-A1 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-20110207946-A1 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-7973182-B2 | enantiomerically pure 1-substituted-3-amino-alcohols, particularly of (S)-(-)- and (R)-(+)-3-N-methylamino-1-(2-thienyl)-1-propanol, by asymmetrically hydrogenating salts of a carboxylic acids with an aminoketone of the formula: | LONZA LTD. (CH) | 2011-07-05 | — | — | US | disclosed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207946-A1 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | ALDH7A1, BCKDK, AASDHPPT | DRD1 303/4885MAP3K14 786/4885SMN1; SMN2 2909/4885 |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | DRD1 3110/4885MAP3K14 32/4885SMN1; SMN2 4508/4885 |
| US-20110207945-A1 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | ALDH7A1, KHK, BCKDK | DRD1 515/4885MAP3K14 717/4885SMN1; SMN2 3184/4885 |
| US-20120316350-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE 1-SUBSTITUTED-3-AMINOALCOHOLS | CYP2S1, AKR1C3, AKR1B10 | DRD1 333/4885MAP3K14 635/4885SMN1; SMN2 3496/4885 |
| US-20160257687-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | DRD1 3110/4885MAP3K14 32/4885SMN1; SMN2 4508/4885 |
| US-20130253190-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | DRD1 3110/4885MAP3K14 32/4885SMN1; SMN2 4508/4885 |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | DRD1 3110/4885MAP3K14 32/4885SMN1; SMN2 4508/4885 |
| US-20130253191-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | DRD1 3110/4885MAP3K14 32/4885SMN1; SMN2 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.